International Journal of Hematology and Oncology 2023, Vol 33, Num 4 Page(s): 209-214
The Results of Patients with Uterine Sarcoma Treated with Adjuvant Radiotherapy

Aylin F. KORCUM1, Gamze AKSU1, Mustafa ÖZDOĞAN2, Tayyup ŞİMŞEK3, Gülgün ERDOĞAN4, Nina TUNÇEL1

1Akdeniz Üniversitesi Tıp Fakültesi Radyasyon Onkolojisi Anabilim Dalı, ANTALYA
2Akdeniz Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Anabilim Dalı, ANTALYA
3Akdeniz Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum Anabilim Dalı, ANTALYA
4Akdeniz Üniversitesi Tıp Fakültesi Patoloji Anabilim Dalı, ANTALYA

Keywords: Uterine Sarcoma, Surgery, Radiotherapy, Chemotherapy
We aimed to analyse prognostic factors and treatment results of patients with uterine sarcoma. Between 1999–2007, twenty women treated with postoperative radiotherapy were evaluated retrospectively. Mean age was 47 years (29- 73). Median follow-up was 34 months (12-84). All patients were treated with postoperative radiotherapy. Histopathologic examination showed: leiomyosarcoma in 11 patients, endometrial stromal sarcoma in 7 and carcinosarcoma in 2. Stage IB, IC, IIIA, IIIB and IIIC tumors were identified in 4, 10, 3, 1 and 2 patients, respectively. At the time of analysis, 4 patients were dead due to progressive disease; 1 patient was alive with disease and 15 were alive without disease, with a median survival of 75 months. Age, menapousal status, stage, histology, grade, lymph node and lymphovascular involvement, chemotherapy were not found to be statistically significant prognostic factor for disease control and overall survival in univariate and multivariate analysis. This study demostrated that adjuvant radiotherapy was effective and tolerable treatment to improve locoregional control.